not sure if many of you have holdings in other medtechs and biotechs but when I look at those i hold and have held i cant think of one that didnt have i some aspect delays or set backs or in some cases outright failures.
Just reading RAP annual report :
the company has been listed for ~4 years
2019 revenue ~$95K, 2018 revenue ~$87K.
Not sure exactly how much raised for clinical trials for the cough app but a fair bit from memory, and had some clinical failures.
Now after 4 years it finally has its first CE approval for 1 indication.
2019 Net Loss for Period ~$5.44M; 2018 Net loss for period ~$6.53M
What they have going for them is loyal shareholders up and down.
Pretty happy that Gmed has clinical trial successes, many Regulatory approvals granted, and owns a china facility and some revenue generating USA operations. feels like the ranters on here probably caught on the wrong side of a trade otherwise they would understand the sector they are investing in more so and what it takes to get new products into a new market.
- Forums
- ASX - By Stock
- GMV
- Ann: Suspension from Official Quotation
Ann: Suspension from Official Quotation, page-146
-
- There are more pages in this discussion • 116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online